Comparative Effectiveness and Safety of Roxadustat versus Erythropoiesis-Stimulating Agents in Patients Receiving Maintenance Hemodialysis: A Real-World Cohort Study.

ABSTRACT:

Introduction

Renal anemia, a common complication of chronic kidney disease (CKD), is traditionally managed with erythropoiesis-stimulating agents (ESAs), which carry cardiovascular risks. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, offers a novel mechanism by enhancing erythropoietin production and iron metabolism. While randomized controlled trials demonstrate its efficacy, real-world data on long-term safety and effectiveness remain limited.

Methods

This retrospective study analyzed 6,414 hemodialysis patients with renal anemia from a single center (December 2018-December 2023), comparing roxadustat (n = 3,184) and ESA (n = 3,230) groups. Propensity score matching was used to balance the baseline characteristics. Efficacy outcom

SUBMITTER: Zhang Z 

PROVIDER: S-EPMC12659449 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature